GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (LSE:RUA) » Definitions » Valuation Rank

RUA Life Sciences (LSE:RUA) Valuation Rank


View and export this data going back to 2002. Start your Free Trial

What is RUA Life Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

RUA Life Sciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

RUA Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (LSE:RUA) » Definitions » Valuation Rank
Comparable Companies
LSE:MHC LSE:BELL LSE:SUN LSE:POLX LSE:IHC ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH STE PODD XSWX:SOON TSE:7733 SHSE:688271
Traded in Other Exchanges
AOHA:Germany
Address
2 Drummond Crescent, Ayrshire, Scotland, Irvine, GBR, KA11 5AN
Website
https://www.rualifesciences.com
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.